搜索公司,投資者……

預測你的未來投資

回曆2月合作夥伴公司的標誌
風險資本
safar.partners

投資

30.

基金

1

回曆2月合作夥伴

回曆2月合作夥伴是一個種子,成長期的風險基金主要投資於技術公司的麻省理工學院、哈佛大學、羅切斯特大學。我們在清潔技術投資平台技術和先進材料,AI /機器人,和生命科學/醫療設備領域。

總部的位置

一個百老彙14樓

劍橋,馬薩諸塞州,02142年,

美國

想告知投資者類似回曆2月合作夥伴關於你的公司嗎?

提交你的分析師簡報在投資者麵前,CB Insights的平台上的客戶和合作夥伴。188bet游戏

最新的回曆2月合作夥伴新聞

協奏曲生物科學宣布發現主動防治複發性陰道酵母菌感染小說活微生物產品的。

2023年6月20日

分享這篇文章提供的新聞分享這篇文章合奏3號(實體- 003)在發展解決酵母菌病——一種陰道酵母菌感染,抗真菌治療複發提供有限的保護。劍橋,質量。,June 20, 2023 /PRNewswire/ -- Concerto Biosciences today announced the launch of a discovery endeavor to develop a new microbial product for the treatment of vulvovaginal candidiasis (VVC), a vaginal yeast infection that adversely affects 75% of women at some point during their lifetimes. Approximately 1.5 million women in the U.S. experience more than four episodes of symptomatic VVC per year. "All available drugs on the market fail to address the recurrent nature of this disease," said Concerto Cofounder and CEO Cheri Ackerman. "It's this recurrence that can be debilitating for women, both physically and emotionally. That's why we're developing a strategy to decrease not only the severity but also the frequency of these episodes." Yeast infections are typically treated with topical or oral antifungals designed to kill the causal agent, Candida albicans. Concerto's product will instead tap into the protective capability of vaginal microbes, some of which naturally work together to pacify C. albicans and prevent disease. Concerto's Ensemble No.3 (ENS-003) will consist of an optimal combination of live microbes, rigorously selected among millions of possible combinations within the vaginal microbiome, to keep C. albicans in a state that does not cause harm. The selection of ENS-003's constituent microbes will be enabled by Concerto's kChip discovery engine . With kChip, Concerto will construct millions of defined microbial combinations—each representing one possible candidate for ENS-003—among which the Concerto team can pinpoint the optimal combination. The team will further train AI models on the massive data sets collected with kChip to fully map the behavior of all possible combinations of vaginal microbes. "We will essentially 'solve' the microbial ecology of the vagina in the context of this disease," said Jared Kehe, Cofounder and Chief Scientific Officer of Concerto. "It's an exciting goal, requiring a tremendous data set and a synthesis among human, microbial, and artificial intelligences. Concerto uniquely possesses the ability to perform this kind of highly complex analysis." Concerto applies the same kChip discovery method to find breakthrough microbe-based products across many industries, primarily in the context of co-discovery partnerships with other companies. "Microbial relationships contain the secrets of unimaginably innovative products—everywhere," said Kehe. "The skin, gut, mouth, and vagina all contain protective microbes, as does the soil, livestock and pets, even your kitchen counter. We work with other companies to solve problems anywhere that microbes grow." Since launching in 2020, Concerto has discovered Ensemble No.2 (ENS-002), a specific combination of skin-dwelling microbes intended to correct the microbial deficiency underlying eczema. This product candidate is currently being optimized for initiation of a first-in-human study in 2024. Building off that success, ENS-003 is an example of the company's generalization of the kChip platform to product development across human health, agriculture, animal health, and consumer needs. Concerto completed a $23 million Series A fundraise in November 2022 led by Safar Partners and joined by Horizons Ventures and M Ventures. In April, Cofounder and CEO Cheri Ackerman was selected by Ernst & Young LLP (EY US) as an Entrepreneur Of The Year® 2023 New England Award finalist. About Concerto Biosciences Concerto Biosciences explores the microbial world with unmatched experimental depth to find breakthrough microbe-based products. Natural microbial communities all around us are our inspiration: They can improve human health, enhance food quality, and boost crop yield. Creating products that harness these complex capabilities requires an unprecedented understanding of how microbial communities behave. Concerto therefore invented a kChip platform that physically constructs millions of miniature, defined microbial communities simultaneously. By observing the behavior of each community, Concerto learns which microbes, prebiotics, and metabolites drive the behavior of natural communities. In partnership with a diverse array of biotech and biopharma companies, Concerto develops these as products. In our first endeavor, Concerto constructed >6 million communities of skin-dwelling microbes to discover an eczema-alleviating "ensemble" of bacteria that pacifies pathogenic S. aureus. We have since initiated discovery projects in women's health, gut health, and agriculture. With its partners, Concerto is unleashing a new era of microbial research and a treasure trove of microbe-based products. To learn more about Concerto Biosciences, visit www.concertobio.com . SOURCE Concerto Biosciences

回曆2月投資合作夥伴

30投資

回曆2月合作夥伴了30投資他們最新的投資Veo機器人作為他們的一部分B - II係列2023年4月4日

CBI的標誌

回曆2月合作夥伴投資活動

投資表

日期

公司

新的嗎?

共同投資者

來源

4/25/2023

B - II係列

Veo機器人

14美元

是的

3

3/28/2023

一個係列

超大杯的技術

28.8美元

是的

6

2/2/2023

一個係列

梯度

18美元

是的

7

1/17/2023

B係列

訂閱看到更多

99美元

訂閱看到更多

10

10/18/2022

種子風投

訂閱看到更多

99美元

訂閱看到更多

10

日期

4/25/2023

3/28/2023

2/2/2023

1/17/2023

10/18/2022

B - II係列

一個係列

一個係列

B係列

種子風投

公司

Veo機器人

超大杯的技術

梯度

訂閱看到更多

訂閱看到更多

14美元

28.8美元

18美元

99美元

99美元

新的嗎?

是的

是的

是的

訂閱看到更多

訂閱看到更多

共同投資者

來源

3

6

7

10

10

回曆2月合作夥伴基金的曆史

1基金曆史

回曆2月合作夥伴1 基金,包括回曆2月合作夥伴基金

截止日期

基金

基金類型

狀態

來源

5/7/2021

回曆2月合作夥伴基金

191.8美元

2

截止日期

5/7/2021

基金

回曆2月合作夥伴基金

基金類型

狀態

191.8美元

來源

2

回曆2月合作夥伴團隊

2團隊成員

回曆2月合作夥伴2 團隊成員,包括當前的管理合夥人,一邊撫摸Chesonis

的名字

工作經曆

標題

狀態

一邊撫摸Chesonis

蔓越莓資本,PAETEC控股

管理合夥人

當前的

訂閱看到更多

訂閱看到更多

訂閱看到更多

的名字

一邊撫摸Chesonis

訂閱看到更多

工作經曆

蔓越莓資本,PAETEC控股

標題

管理合夥人

訂閱看到更多

狀態

當前的

訂閱看到更多

發現正確的解決方案為您的團隊

CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。

請求一個演示

CBI的網站通常使用一些餅幹,使更好的相互作用我們的網站和服務。使用這些餅幹,這可能是存儲在你的設備上,允許我們的改進和定製你的經曆。你可以閱讀更多關於你的餅幹的選擇在我們的隱私政策在這裏。繼續使用這個你同意這些選擇。

Baidu
map